Homelessness and HIV share common risk factors, according to Julie Dombrowski, M.D., M.P.H., professor of medicine at the University of Washington and director of HIV treatment initiatives at the King County, Seattle public health department.
Finding a cure for inflammatory bowel disease (IBD) would mean reducing treatment waste, according to Ashwin N. Ananthakrishnan, M.D., M.P.H., MGH, associate professor of medicine at Massachusetts General Hospital and Johan Burisch, M.D., Ph.D., a gastroenterologist at Hvidovre Hospital in Denmark.
High costs and the novelty and complexity of new therapies such as gene therapy present social determinants of health and health literacy challenges, says Tiara Green, president of Accessia Health
Cost is a barrier to care for chronic and rare diseases, so financial assistance is way to lower that barrier and help people manage their health condition, says Green, president of Accessia Health
Digital pharmacy solutions can help brick and mortar locations become more efficient, according to Sarah Thomas, VP of sales and commercialization at HealthDyne and David Skomo, COO of HealthDyne.
A panelist discusses how the adoption of C-peptide preservation as a critical end point in clinical trials represents a paradigm shift in type 1 diabetes (T1D) research, moving beyond glucose control alone to focus on disease-modifying therapies that can maintain endogenous insulin production and potentially alter the fundamental course of the disease.
A growing and more diverse pipeline means that there is a greater need for digital innovations, which can address affordability, access and industry collaboration, according to Sarah Thomas, VP of sales and commercialization at HealthDyne and David Skomo, COO of HealthDyne.
Becky Davis of Charles River Associates predicts that an influx of new and oral GLP-1 drugs, along with pricing pressures from policy and competition, will reshape the weight loss drug market in the next two years.
At the 2024 Asembia Specialty Pharmacy Summit, Becky Davis, principal at Charles River Associates, discussed how employer-based insurance coverage for GLP-1s remains uneven—and what factors are influencing decisions about access to these weight-loss treatments.
